GO
Loading...

Enter multiple symbols separated by commas

Amgen Inc

More

  • May 22- Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop an inflammation drug after it observed suicidal thoughts in the subjects of a trial. AstraZeneca could decide on the development and marketing of the drug for all territories, except for Japan and certain Asian territories, where Kyowa Hakko Kirin has the rights to it, Amgen...

  • May 22- Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop an inflammation drug after it observed suicidal thoughts in subjects of a trial. AstraZeneca could decide on the development and marketing of the drug for all territories, except for Japan and certain Asian territories, where Kyowa Hakko Kirin has the rights to it, Amgen...

  • May 22- EU Medicines Agency:. *EU Medicines Agency recommendations for May 2015. *Recommends approval of cholesterol drug Repatha from Amgen Inc.

  • Beware of bond bubble forming in ETFs Wednesday, 20 May 2015 | 2:08 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Should you invest in fixed income when corporations are all too eagerly selling new bonds in staggeringly large amounts? Likely not.

  • LONDON, May 19- Amgen's new cholesterol drug Repatha could be recommended for approval in Europe as early as this week, putting it ahead in a race with a rival product from Sanofi. Recommendations for marketing approval by its Committee for Medicinal Products for Human Use are normally endorsed by the European Commission within a couple of months.

  • DuPont win over Peltz is a win for investors Thursday, 14 May 2015 | 11:42 AM ET
    Nelson Peltz

    DuPont's win over activist investor Nelson Peltz is a victory for long-term shareholders, says former Medtronic CEO Bill George.

  • Investors were waiting for news that could move share prices from many bigger companies including Bristol-Meyers Squibb Co, Amgen Inc and Celgene Corp. Hot topics at the American Society of Clinical Oncology conference in Chicago will include immuno oncology and CAR-T cell therapies. Shares in Juno Therapeutics Inc, Kite Pharma Inc, BlueBird Bio Inc and...

  • Biotech investors: These are the key names to know Wednesday, 13 May 2015 | 11:53 AM ET
    Biotech

    Ahead of the world's biggest cancer research conference, the American Society of Clinical Oncology meeting, here are the companies to watch.

  • --Amgen in late 2012 bought Decode Genetics for $415 million in cash to gain access to a database of complete genetic sequences of 2,636 Icelanders. --In January 2014, Regeneron Pharmaceuticals Inc signed a deal with Geisinger Health System in Pennsylvania to sequence DNA from as many as 250,000 volunteers from Geisinger's pool of 3 million patients.

  • Regeneron Pharmaceuticals Inc, which signed a deal with Pennsylvania's Geisinger Health System in January 2014 to sequence partial genomes of some 250,000 volunteers, is already claiming discoveries based on the new approach. Pfizer Inc, Roche Holding AG and Biogen Inc are working on similar projects that use DNA and patient health data to find new drug...

  • May 7- A U.S. appeals court has blocked the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, the blockbuster Amgen Inc drug used to prevent infections in cancer patients. The U.S. Court of Appeals for the Federal Circuit ruled on Tuesday, however, that the injunction could take effect while Amgen's appeal is pending. The Novartis drug, Zarxio,...

  • May 7- A U.S. appeals court has blocked the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, Amgen Inc's blockbuster drug used to prevent infections in cancer patients. The U.S. Court of Appeals for the Federal Circuit ruled on Tuesday, however, that the injunction could take effect while Amgen's appeal is pending. The Novartis drug, Zarxio,...

  • May 7- Regeneron Pharmaceuticals Inc said it expects sales of blockbuster eye drug Eylea to grow even more quickly following data that showed it was superior to rival treatments. Sales of Eylea in the United States leapt 51 percent to $541 million in the first quarter ended March 31, helping the company's adjusted profit handsomely beat the average analyst...

  • Stocks are a buy so ignore the gloom: Technician Sunday, 3 May 2015 | 10:57 AM ET
    Wall Street

    Stocks finished off the month with a whimper, but Oppenheimer technical analyst Ari Wald says the sell-off is a great buying opportunity.

  • Biotech bust may be sending message about stocks Thursday, 30 Apr 2015 | 5:03 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Traders are watching the iShares Nasdaq Biotechnology ETF for clues on whether a deeper stock market decline is on the horizon.

  • April 29- Amgen Inc's skin cancer immunotherapy showed enough efficacy in the treatment of melanoma to be given marketing approval, an independent advisory panel to the U.S. Food and Drug Administration said on Wednesday. Amgen said on Wednesday that T-Vec was more effective in melanoma patients whose cancer had not spread to internal organs.

  • April 29- Amgen Inc's skin cancer immunotherapy showed enough efficacy in the treatment of melanoma to be given marketing approval, an independent advisory panel to the U.S. Food and Drug Administration said on Wednesday. The panel voted 22-1 supporting an approval for the therapy, talimogene laherparepvec or "T-Vec", an engineered virus that kills cancer...

  • April 29- Pharmacy benefit manager Express Scripts Holding Co, which has aggressively negotiated lower costs of new hepatitis C drugs, on Wednesday said a new "focus area" will be subduing costs of a growing wave of pricey biotech cancer drugs. "This is going to be a much slower and much bigger effort over time than what you saw for hepatitis," Steve Miller, chief...

  • There's a crowding out effect, "said Stanley Sun, interest rate strategist at Nomura Securities International in New York. Large corporate deals competed for investors' dollars, with Amgen and Oracle bringing out multi-part issues worth $3.5 billion and $10 billion, respectively, according to IFR, a Thomson Reuters unit. The Treasury Department sold $35...

  • *U.S. to sell $35 bln 5- year notes as FOMC sets to meet. NEW YORK, April 28- U.S. "The deals are weighing on the market whether it's rate-locking or just an increase in net supply," said Sean Murphy, a Treasuries trader at Societe Generale in New York.